Showing 1 - 6 results of 6 for search 'A. L. Bakulev', query time: 0.04s Refine Results
  1. 1
    Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

    Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study by T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova

    Published 2020-11-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

    Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study by T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study

    Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study by T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaidukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease)

    Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in pati... by D. I. Abdulganieva, A. L. Bakulev, E. А. Belousova, L. F. Znamenskaya, T. V. Korotaeva, L. S. Kruglova, M. M. Kokhan, A. M. Lila, V. R. Khairutdinov, I. L. Khalif, M. M. Khobeish

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion

    Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion by D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina, O. B. Shchukina

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial

    Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, mult... by Т. V. Korotaeva, A. V. Samtsov, A. L. Bakulev, M. M. Kokhan, I. K. Minullin, O. A. Vylegzhanina, V. V. Dubensky, B. V. Khalilov, A. A. Khotko, O. S. Zykova, I. V. Chumachenko, A. M. Lukyanov, A. V. Artemyeva, S. I. Derbin, E. Yu. Stukalina, E. V. Chernyaeva, R. A. Ivanov

    Published 2018-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: